Regarding other AEs of interest, myelodysplastic syndrome, acute myelocytic leukemia or aplastic anemia occurred in 11 participants in the PARP inhibitor group (6 in the PAOLA-1 [24] trial, 3 in the SOLO1 [23] trial, 1 in each of the other two trials) and in 2 participants in the placebo group (1 in the PAOLA-1 [24] trial and 1 in the SOLO1 [23] trial). Here, PARP1 is linked to aplastic anemia.